South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the biosimilar of Humira to Norway.
The company has won the Norwegian government's tender for autoimmune disease treatment. It will provide Remsima SC and Yuflyma from this month until 2026.
According to the company, the Norwegian government has created a foundation for expanding product prescriptions, thanks to policies encouraging biosimilar and regulations on drug prices to enhance medical accessibility and ease financial burdens.
The two products will be sold directly by the local subsidiary.
Celltrion plans to pursue an evidence-based marketing strategy by securing prescription data through consultation with the Norwegian government and healthcare institutions.
It aims to expand prescriptions across the entire Nordic region through a data-driven marketing strategy.